 |
2021 News Releases
April 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Read
March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Read
February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Read
February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Read
February 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Read
January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read
January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read
January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read
January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
